Paxillin (PXN) is required for receptor tyrosine kinase-mediated ERK activation, and the activation of the Raf/MEK/ERK cascade has been linked with Bcl-2 expression. We hypothesized that phosphorylation of PXN by the EGFR/Src pathway might contribute to cisplatin resistance via increased Bcl-2 expression. We show that cisplatin resistance was dependent on PXN expression, as evidenced by PXN overexpression in TL-13 and TL-10 cells and PXN knockdown in H23 and CL1-5 cells. Specific inhibitors of signaling pathways indicated that the phosphorylation of PXN at Y118 and Y31 via the Src pathway was responsible for cisplatin resistance. We further demonstrated that ERK activation was also dependent on this PXN phosphorylation. Bcl-2 transcription was upregulated by phosphorylated PXN-mediated ERK activation via increased binding of phosphorylated CREB to the Bcl-2 promoter. A subsequent increase in Bcl-2 levels by a PXN/ERK axis was responsible for the resistance to cisplatin. Animal models further confirmed the findings of in vitro cells indicating that xenograft tumors induced by TL-13-overexpressing cells were successfully suppressed by cisplatin combined with Src or ERK inhibitor compared with treatment of cisplatin, Src inhibitor or ERK inhibitor alone. A positive correlation of phosphorylated PXN with phosphorylated ERK and Bcl-2 was observed in lung tumors from NSCLC patients. Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors. Collectively, PXN phosphorylation might contribute to cisplatin resistance via activating ERK-mediated Bcl-2 transcription. Therefore, we suggest that Src or ERK inhibitor might be helpful to improve the sensitivity for cisplatin-based chemotherapy in NSCLC patients with PXN-positive tumors.
INTRODUCTION
Paxillin (PXN) is a 68-kDa focal adhesion protein that functions as an adapter protein. It is phosphorylated by FAK and Src after integrin engagement and in turn binds to other downstream proteins, facilitating their recruitment into the signal cascade. [1] [2] [3] Phosphorylation of PXN seems essential for maintaining the labile adhesions required for cell migration. 4, 5 Our previous report indicated that PXN overexpression via the reduction of microRNA-218 promotes tumor progression and may predict poor overall survival (OS) in non-small cell lung cancer (NSCLC) patients. 6 Recent reports indicated that aggressive tumor growth as a consequence of the epithelial-mesenchymal transition was associated with anti-apoptosis for drug resistance, which resulted in poor tumor response in patients who received cisplatin-based chemotherapy. [7] [8] [9] Therefore, PXN overexpression and its phosphorylation might be associated with tumor progression and drug resistance.
PXN is required for receptor tyrosine kinase-mediated activation of ERK. 3, 5, [10] [11] [12] EGFR activation leads to the phosphorylation of tyrosine residues on PXN, most likely by EGFR and Src. 11, 12 This tyrosine phosphorylation of PXN is required for downstream activation of Raf, MEK and ERK, 3, 11, 12 and the activation of the Raf/ MEK/ERK cascade is linked with Bcl-2 expression. [13] [14] [15] [16] [17] [18] Therefore, we hypothesized that phosphorylation of PXN by the EGFR and Src pathway might increase Bcl-2 expression via ERK activation, and consequently result in resistance to cisplatin.
Our preliminary immunohistochemistry data showed that PXN expression was positively correlated with phosphorylation of PXN at Y118 and Y31. In addition, a prognostic significance of phosphorylation at Y118 and Y31 on survival and relapse was observed in a subset of lung cancer patients. Therefore, we performed mechanistic studies on a cell model to investigate whether PXN and its phosphorylation could modulate the resistance to cisplatin. We further verified which signaling pathway could be responsible for the phosphorylation of PXN, and whether PXN phosphorylation could promote resistance to cisplatin via ERK-mediated Bcl-2 expression, as Bcl-2 interacts with the LD4 motif of PXN to promote cell survival. [19] [20] [21] Cisplatin resistance induced by PXN-mediated Bcl-2 expression via ERK activation was further verified in xenograft tumors of nude mice using Src or ERK inhibitor. The tumor response in patients who received cisplatin-based chemotherapy was investigated to understand whether PXN and its phosphorylation could be associated with tumor response and patient survival.
RESULTS
PXN may confer resistance to cisplatin in lung cancer cells A panel of lung cancer cells was enrolled to examine the possibility that PXN could confer resistance to cisplatin, determined by MTT assays. Ten lung cancer cell lines were treated with four doses of cisplatin and the dose response curve was used to calculate the concentration that yielded 50% inhibition (IC50). PXN mRNA expression levels in each lung cancer cell line were positively correlated with the IC50 for cisplatin (Figure 1a ). This result suggests that PXN levels might be associated with the resistance to cisplatin in lung cancer cells.
We investigated this possibility further using H23 and CL1-5 cells, which had the highest cisplatin IC50 values and TL-13 and TL-10 cells, which had the lowest IC50 values. The H23 and CL1-5 cells were transfected with two PXN RNAi while the TL-13 and TL-10 cells were transfected with two doses of the GFP-PXN expression vector. As expected, PXN expression, evaluated by western blotting, was decreased in PXN-knockdown cells and increased in PXN-overexpressing cells (Figure 1b) . The IC50 value was decreased by PXN knockdown in the H23 and CL1-5 cells when compared with their parental and non-specific RNAi transfection control (NC) cells (9.5 mM and 10.9 mM vs 26.9 mM and 26.2 mM for H23; 8.7 mM and 10.2 mM vs 21.2 mM and 20.5 mM for CL1-5; Figure 1b) . Conversely, the IC50 value was increased by PXN overexpression in TL-13 and TL-10 cells as compared with their parental and vector control (VC) cells (26.0 mM and 19.8 mM vs 7.5 mM and 6.7 mM for TL-13; 24.5 mM and 15.4 mM vs 7.5 mM and 8.7 mM for TL-10; Figure 1b) . Annexin-V/PI assay was performed to test whether cell apoptosis could be responsible for the cell viability reduced by cisplatin. The representative cisplatin-induced apoptotic cells in PXN-knocked down H23 and PXN-overexpressing TL-13 cells are shown in Figure 1c . The cell viability reduced by cisplatin in PXN-knocked down H23 and CL1-5 cells and PXN-overexpressing TL-13 and TL-10 cells was consistent with apoptotic cells (Figure 1d ). These results clearly indicate that PXN expression may confer resistance to cisplatin in lung cancer cells. Figure 1 . PXN expression may confer cisplatin resistance via anti-apoptotic mechanisms. (a) Ten lung cancer cell types were treated with four doses of cisplatin and the dose-response curves were used to calculate the 50% inhibition concentration (IC50). PXN mRNA expression levels in each lung cancer cell type were examined by real-time PCR. (b) Two different PXN knockdown plasmids were transfected into high-PXNexpressing (H23 and CL1-5) cell lines. Alternatively, increasing amounts of expression plasmid were transfected into low PXN expressing (TL-13 and TL-10) cell lines. The total amount of transfected DNA was kept constant by adding the control vector. After 48 h, the lysates were harvested and evaluated for levels of PXN and b-actin protein by western blotting. b-actin was used as a protein-loading control. P: parental control. NC: non-specific RNAi control. VC: vector control. PXN-knocked down or PXN-overexpressing lung cancer cells were treated with four doses of cisplatin and the dose-response curves were used to calculate the IC50 value. (c) Flow cytometric analysis of apoptosis after annexin V and PI staining. Indicated cells were treated with 0.1% DMSO or 25 mM cisplatin for 48 h. The cells were then subjected to annexin V and PI staining, followed by flow cytometry. (d) Percentage of apoptotic cells including with the Annexin V þ /PI À population (early apoptosis) plus Annexin V þ /PI þ (late apoptosis/secondary necrosis) was summarized by flow cytometric analysis. Data are expressed as means ± s.d., n ¼ 3.
The EGFR, Src and ERK pathways might be responsible for the resistance to cisplatin in phosphorylated PXN-overexpressing lung cancer cells PXN phosphorylation is expected to be associated with the resistance to cisplatin and its phosphorylation may be mediated through the JNK, NF-kB, PI3K/AKT, EGFR, Src, and MEK/ERK signaling pathways. 1, 5, [10] [11] [12] [22] [23] [24] [25] [26] We examined which signal pathway(s) could be responsible for the resistance to cisplatin in lung cancer cells by combining the specific inhibitor of each signaling pathway with cisplatin to treat high-PXN-expressing H23 cells. The percentage of apoptotic cells induced by cisplatin in H23 cells was increased by B18% by c-Met inhibitor (SU11274), B11% by JNK inhibitor (SP600125), B20% by EGFR inhibitors (PD153035 and Gefitinib) and B40% by Src (PP2 and Dasatinib) and MEK/ERK inhibitors (U0126 and AZD6244) (Figure 2a, upper panel) . However, the percentage of apoptotic cells induced by cisplatin in H23 cells was not changed by inhibitors of NF-kB (BAY11-7082), PI3K/AKT (LY294002 and wortmannin) or p38/MAPK (SB203580) (Figure 2a, upper panel) . Similarly, cisplatin-induced apoptosis in PXN-overexpressing TL-13 cells was increased by EGFR inhibitors (PD153035 and Gefitinib), Src (PP2 and Dasatinib) and MEK/ERK inhibitors (U0126 and AZD6244) (Figure 2a, down panel) . Cisplatin resistance due to PXN overexpression via the EGFR, Src, and ERK signaling pathway was further confirmed by direct knockdown of EGFR, Src and ERK, respectively (Figure 2b ). These results suggest that EGFR, Src and MEK/ERK pathway might contribute to the resistance to cisplatin in lung cancer cells with high PXN expression.
We next examined the possibility that phosphorylation of PXN could be mediated through EGFR, Src and MEK/ERK signaling pathway, giving rise to cisplatin resistance in lung cancer cells with high PXN expression. The expression levels of PXN phosphorylated at Y118 and Y31 was not changed by ERK inhibitors (U0126 and AZD6244) in H23 cells or PXN-overexpressing TL-13 cells (Figure 2c) . Conversely, phosphorylated PXN levels were reduced to a greater extent by Src inhibitors (PP2 and Dasatinib) than by EGFR inhibitors (PD153035 and Gefitinib) in H23 and PXNoverexpressing TL-13 cells (Figure 2c ). We also observed that phosphorylated ERK levels were markedly decreased by Src and EGFR inhibitors in both cell types. As expected, phosphorylated Src and ERK expression levels were suppressed by Src and ERK inhibitors in both cell types (Figure 2c ). These results were further confirmed by direct knockdown of EGFR, Src and ERK, respectively ( Figure 2d ). We thus suggest that the phosphorylation of PXN at Y118 and Y31 is predominately regulated by the EGFR-mediated Src pathway, not by the ERK pathway.
Phosphorylation of PXN at Y118 and Y31 is required for ERKmediated Bcl-2 and Mcl-1 expressions, but Bcl-2 has a more important role than Mcl-1 in cisplatin resistance Phosphorylation of PXN by HGF may activate ERK phosphorylation via promotion of the interaction between PXN and Raf in mouse epithelial cells, 10 and ERK activation is associated with elevated Bcl-2 expression. [13] [14] [15] [16] [17] [18] We therefore explored the possibility that PXN phosphorylation at Y118 and Y31 could activate ERK phosphorylation to promote Bcl-2 transcription induced via increased CREB phosphorylation. The phosphorylation of PXN and ERK were concomitantly decreased by PXN knockdown in H23 cells, but the phosphorylation of both molecules was increased by PXN overexpression in TL-13 cells in a dose-dependent manner ( Figure 3a ). This result suggests that PXN expression could be associated with the phosphorylation of ERK.
Expression vectors for PXN mutations at Y118 and/or Y31 were constructed by site-directed mutagenesis. Mutated PXN expression vectors were transfected into TL-13 cells to explore whether phosphorylation of ERK could be abrogated by the mutation of PXN phosphorylation at Y118 or Y31. As expected, PXN phosphorylation at Y118 or Y31 was only observed in TL-13 cells with mutated PXN-Y31 or PXN-Y118 expression vectors (Figure 3b Upregulation of Bcl-2 transcription by PXN-mediated ERK activation is through increased phosphorylation of CREB binding to Bcl-2 promoter We next examined the possibility that ERK activation by PXN phosphorylation may upregulate Bcl-2 transcription via phosphorylation of CREB (p-CREB). 13, 15, 27 Western blotting data showed that p-CREB and Bcl-2 expression were concomitantly decreased by PXN knockdown in H23 cells (Figure 4a, left panel) . More interestingly, the p-CREB and Bcl-2 expressions were markedly reduced in PXN-overexpressing TL-13 cells following transfection with PXN-Y118-mutated, Y31-mutated or double-mutated expression vectors when compared with TL-13 cells transfected with a wild-type PXN expression vector (Figure 4a , right panel). In addition, Luciferase reporter assay and real-time PCR analysis showed that the reporter activity of Bcl-2 promoter and its mRNA expression were significantly decreased by PXN knockdown in H23 cells and were increased by PXN overexpression in TL-13 cells (Figure 4a , lower panel). P-ERK, p-CREB and Bcl-2 expressions were decreased by ERK inhibitors, and ERK knockdown in H23-and PXN-overexpressing TL-13 cells (Figure 4b, upper panel) . The p-CREB to the Bcl-2 promoter, evaluated by chromatin immunoprecipitation (ChIP), was significantly decreased by ERK inhibitors, and ERK knockdown in H23-and PXN-overexpressing TL-13 cells (Figure 4b , middle panel). In addition, Luciferase reporter assay and real-time PCR analysis showed that the reporter activity of Bcl-2 promoter and its mRNA expression were significantly decreased by ERK inhibitors and ERK knockdown in H23-and PXN-overexpressing TL-13 cells (Figure 4b, lower panel) . Collectively, we suggested that ERK activation by PXN phosphorylation may upregulate Bcl-2 transcription via phosphorylation of CREB (p-CREB).
PXN-mediated xenograft tumors were more effectively suppressed by cisplatin combined with Dasatinib or AZD6244 As previously described, we expected that PXN-mediated cisplatin resistance can be dissolved by Src or ERK inhibitor via decreased Bcl-2 expression. The representative xenograft tumors in each group of nude mice were shown in Figure 5a . The tumor volume in nude mice with TL-13 VC cell injection was grown slowly during 7-27 days, but the tumor volume of the nude mice with VC cells injection was almost suppressed by cisplatin treatment (VC vs VC þ Cisplatin; Figure 5b , left panel). However, the tumor volume of nude mice with PXN-overexpressing TL-13 cells injection was increased markedly during the time intervals; surprisingly, the tumor volume of nude mice with PXN-overexpressing TL-13 cells injection was almost not changed by cisplatin treatment (PXN vs PXN þ Cisplatin; Figure 5b , left panel). More interestingly, the tumor volume of nude mice injected with PXN-overexpressing TL-13 cells was decreased markedly by cisplatin plus ERK inhibitor AZD6244 or Src inhibitor Dasatinib when compared with PXNoverexpressing TL-13 cells-injected nude mice that were treated with cisplatin, AZD6244 or Dasatinib alone (Figure 5b, right panel) . These results from nude mice model strongly support the findings from the cell experiments.
The correlation of PXN with phosphorylated PXN, phosphorylated ERK and Bcl-2 in lung tumors from NSCLC patients We collected 183 tumors from NSCLC patients to verify whether PXN expression could be associated with the expressions of phosphorylated PXN, phosphorylated ERK and Bcl-2. The representative immunohistochemical results for PXN, PXN phosphorylated at Y118 and Y31, phosphorylated ERK and Bcl-2 are shown in Figure 6a . Immunohistochemistry analysis showed that PXN expression was positively correlated with PXN phosphorylation (phosphorylated Y118 and/or Y31), phosphorylated ERK and Bcl-2 expression in lung tumors (Po0.001 for phosphorylated PXN, P ¼ 0.027 for phosphorylated ERK, P ¼ 0.005 for Bcl-2; Table 1 ). In addition, the correlation of phosphorylated PXN with phosphorylated ERK and Bcl-2 expression (P ¼ 0.003 for phosphorylated ERK, P ¼ 0.015 for Bcl-2; Table 1 ), and the association between phosphorylated ERK and Bcl-2 were also observed in this study population (P ¼ 0.002; Table 1 ). These results were consistent with the findings of the cell model indicating that PXN phosphorylation may elevate Bcl-2 expression via ERK activation.
The prognostic value of PXN and its phosphorylation at Y118 and/ or Y31, phosphorylated ERK and Bcl-2 on OS and relapse-free survival in NSCLC patients PXN overexpression is associated with poor OS in NSCLC patients. We further hypothesized that PXN and its phosphorylated Y118 and/or Y31 forms, phosphorylated ERK and Bcl-2 might be associated with OS and also with relapse-free survival (RFS). Kaplan-Meier analysis showed that patients with tumors positive for PXN and its phosphorylated forms had shorter OS and RFS periods than did those with tumors negative for PXN and its phosphorylated forms (PXN: P ¼ 0.001 for OS, Po0.001 for RFS; phosphorylated PXN: P ¼ 0.005 for OS, Po0.001 for RFS; Figure 6b , left panel). Phosphorylated ERK and Bcl-2 also showed prognostic value for determining OS and RFS in resected NSCLC patients (phosphorylated ERK: P ¼ 0.001 for OS, Po0.001 for RFS; Bcl-2: P ¼ 0.034 for OS, P ¼ 0.038 for RFS; Figure 6b, Table 2 ); however, no independent prognostic value was observed for Bcl-2 in this study population. These results support the findings of the cell models and indicate that PXN phosphorylation may increase ERKmediated Bcl-2 expression, resulting in relapse and poor survival in resected NSCLC patients.
Association of PXN, phosphorylated PXN, phosphorylated ERK, and Bcl-2 with the tumor response in patients who received cisplatinbased chemotherapy A total of 100 of 183 patients who received cisplatin-based chemotherapy after surgical resection were enrolled in this cohort study. The tumor response to cisplatin-based chemotherapy in 100 patients was collected from chart reviews, and the information was further confirmed by at least two medical doctors. We classified patients with stable disease and progressive disease as the unfavorable tumor response group and the partial response group; the complete response was classified as the favorable tumor response group. As shown in Table 3 , patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 had more unfavorable tumor responses than did those with tumors negative for PXN, phosphorylated PXN, phosphorylated ERK, and Bcl-2 (70 vs 41%, P ¼ 0.004 for PXN; 75 vs 39%, Po0.001 for phosphorylated PXN; 71 vs 26%, Po0.001 for phosphorylated ERK; 70 vs 38%, P ¼ 0.001 for Bcl-2; Table 3 ). These results strongly support the findings of the cell model, which showed that the resistance to cisplatin due to PXN phosphorylation may be mediated through ERK-mediated Bcl-2 expression.
DISCUSSION
In the present study, we provide the evidence that phosphorylation of PXN at Y118 and Y31 is required for cisplatin resistance in lung cancer cells. The possible mechanism would involve activation of the ERK-CREB signaling pathway by PXN phosphorylation, leading to the upregulation of Bcl-2 expression in Figure 4 . ERK-mediated Bcl-2 expression was regulated by via phosphorylation of CREB. (a) H23 cells were transfected with two different types of PXN RNAi (1 mg) and 0.5 mg of Bcl-2 P1-Luc reporter. TL-13 cells were transfected with 1 mg of wild-type (WT) or mutated (Y31F, Y118F and Y31/118F) PXN and 0.5 mg of Bcl-2 P1-Luc reporter. Luciferase activity was measured at 48 h post-transfection. In all experiments, the relative luciferase activity was shown as fold-activation relative to that of the control cells. (b) H23 and wild-type (WT) PXN-overexpressing TL-13 cells were treated by U0126, AZD6244, ERK RNAi #1 (p42#1 and p44#1) and #2 (p42#2 and p44#2). After 48 h, the cells lysates were separated by SDS-PAGE for the evaluation of p-CREB, CREB, BCL-2, p-ERK, total ERK and b-actin expressions by western blotting and real-time PCR. For ChIP assay, the lysates were immunoprecipitated by p-CREB, and PCR amplification of immunoprecipitated DNA was carried out with diluted aliquots, using the primers consisting of the oligonucleotides that encompass the promoter region of Bcl-2. Bcl-2 transcriptional activity was evaluated by real-time RT-PCR and luciferase assay. The total amount of transfected DNA was kept constant by adding the control vector. Luciferase activity was measured at 48 h post-transfection. transcriptional levels. Previous studies have indicated that phosphorylation of PXN is dependent on Src activation via the phosphorylation of EGFR and the c-Met pathway. Consistent results were also observed in this study, where an involvement of the EGFR, Src and MEK/ERK pathway was implicated in the phosphorylation of PXN; however, no evidence was obtained for involvement of the PI3K/AKT and MAPK pathways (Figure 2a) . Interestingly, the percentage of apoptotic cells induced by cisplatin in PXN-overexpressing TL-13 cells increased by B40% in response to an EGFR inhibitor, but the percentage of apoptotic cells induced by cisplatin in H23 cells only increased by B20% in response to the same inhibitor. The different impact of EGFR inhibitors on cisplatin cytotoxicity in both cell types was due to the higher expression of c-Met in H23 than in TL-13 cells (Supplementary Figure 1) . The percentage of apoptotic cells induced by cisplatin in H23 cells in response to a c-Met inhibitor SU11274 was similar with that of H23 cells induced by cisplatin in response to EGFR inhibitors (Figure 2a) . We also used EGF and HGF to activate the EGFR and c-Met pathways in H23 cells. Phosphorylated PXN and Src levels were concomitantly increased by EGF and HGF in a dose-dependent manner (Supplementary Figure 1b) . Levels of phosphorylated PXN and Src in H23 cells were further elevated by the combined treatment with EGF and HGF (Supplementary Figure 1c, left panel) . Conversely, the expression levels of phosphorylated PXN and Src were diminished by the combined treatment with SU11274 and Gefitinib (Supplementary Figure 1c, right panel) . These results are consistent with previous reports indicating that the Src pathway can be activated independently by the EGFR and c-Met pathways to phosphorylate PXN. 2, 3, 10, 12, 22, [24] [25] [26] [28] [29] [30] In addition, p-ERK and Bcl-2 expression were synergistically reduced in these lung cancer cells, supporting the idea that phosphorylation of PXN by the Src pathway has a crucial role in cisplatin resistance in lung cancer cells (Supplementary Figure 1c) .
In the present study, PXN-mediated Bcl-2 transcription via ERK activation may be responsible for cisplatin resistance (Figures 2-4) . Notably, PXN phosphorylation at Y118 and Y31 may affect the interaction between PXN LD4 and Bcl-2 BH4 ( Supplementary  Figures 2 and 3a) . In addition, cycloheximide and ubiquitination pattern assay showed that the interaction between PXN and Bcl-2 may increase Bcl-2 protein stability. (Supplementary Figure 3a and  b) . These results suggest that interaction of PXN with Bcl-2 may increase Bcl-2 expression via protecting Bcl-2 protein degraded by ubiquitin proteasomal pathway. PXN LD4 motif is a conserved binding domain to form a complex via recruiting GIT1/b-PIX/Pak or TACE. PXN at S272 has been shown to be phosphorylated by Pak kinase(s). 31, 32 PXN phosphorylation at S272 expression levels in TL-13 cells was almost diminished by Src inhibitors and EGFR inhibitors when compared with those cells without inhibitor treatments (Supplementary Figure 4a) . Cisplatin-mediated cell apoptosis was increased markedly in TL-13 cells with PXN-mutated S272A transfection when compared with those cells with PXN wild-type transfection (Supplementary Figure 4b) . However, the percentage of apoptotic cells were not changed by mutated PXN S85A, S178A and T538A transfection (Supplementary Figure 4b) . Mutated PXN S272A (located at PXN 0 LD4 motif) also abolished the interaction of PXN with Bcl-2 to decrease Bcl-2 expression levels ( Supplementary Figure 4c and d) . Interestingly, PXN phosphorylation at Y118 and Y31 seemed to contribute to PXN phosphorylation at S272 via increased p21 activated kinase (PAK1) phosphorylation due to PAK1 activation (Supplementary Figure 4) . Therefore, Bcl-2 protein stability increased by PXN was not only indirectly via phosphorylation at Y118 and Y31 but also directly via PXN phosphorylation at S272. However, the in vivo xenograft tumors showed that the Src or ERK inhibitor was able to markedly suppress tumor formation in nude mice which were injected with PXN-overexpressing cells and combined with cisplatin treatment. This observation was consistent with the results from the in vitro cell model. Therefore, we suggest that phosphorylation of PXN may contribute more to cisplatin resistance via activating ERKmediated Bcl-2 transcription than Bcl-2 protein stability due to PXN interacting with Bcl-2.
Previous reports indicated that the increase in Bcl-2 expression due to ERK phosphorylation was associated with the survival of estrogen-induced human macrophages, valproate-treated neuron-like cells and pancreatic cancer cells. [13] [14] [15] [16] Bcl-2 has a crucial role in chemoresistance in various human cancers including ovarian, bladder, colorectal, prostate, nasopharyngeal and lung cancers. [33] [34] [35] [36] [37] [38] [39] Therefore, the signaling pathways that increase Bcl-2 expression are important in the reduction of chemoresistance. We showed that PXN phosphorylation is required for ERK activation, and consequently for the upregulation of Bcl-2 transcription via phosphorylation of CREB (Figure 4) . ChIP analysis further indicated that the phosphorylated CREB upregulated Bcl-2 transcription via an increased binding of phosphorylated CREB to the Bcl-2 promoter (Figure 4 ). To the best of our knowledge, this is the first study to indicate that PXN phosphorylation can activate the ERK pathway and, in turn, upregulate Bcl-2 expression via promotion of binding of phosphorylated CREB to the Bcl-2 promoter. We further evidenced that PXN phsphorylation at Y31 and Y118 has a crucial role in the interaction between PXN and Bcl-2 to maintain Bcl-2 protein stability via blocking ubiquitin proteasomal pathway ( Supplementary Figures 2 and 3) . The involvement of two mechanisms in PXN-mediated cisplatin resistance due to increased Bcl-2 expression was further evidenced in TL-13 cells with PXN E268R plus CREB RNAi transfection (Supplementary Figure 5) . Therefore, Bcl-2 expression, elevated by PXN phosphorylation at Y31 and Y118, was responsible for the resistance to cisplatin in lung cancer cells. Previous reports indicated that tumors with high PXN expression were more common in late-stage patients than in early-stage patients.
6,19 PXN protein expression was consistent with its mRNA expression in lung tumors from lung cancer patients. 6, 19 In present study, PXN expression in lung tumors may be used to predict tumor response in patients who received cisplatin-based chemotherapy. Therefore, we expected that PXN mRNA expression in blood plasma could be associated with its expression in lung tumors, and it could be useful as an indicator of the potential effectiveness of cisplatin-based chemotherapy in advanced NSCLC patients. The blood plasma and tumor tissues were obtained from 11 stage-I and stage-II patients and from 67 stage-III and stage-IV patients from another medical center in Central Taiwan (Chung Shan Medical University Hospital, Taichung, Taiwan). PXN mRNA expression was more frequently detected in blood plasma from late-stage patients than in earlystage patients (57 vs 9%, P ¼ 0.007; Supplementary Table 1) . More interestingly, patients with high PXN mRNA tumors were more commonly associated with patients' blood plasma with high PXN mRNA expression levels (64 vs 36%, P ¼ 0.013). Therefore, we suggest that evaluation of PXN mRNA expression in blood plasma may be useful for predicting the tumor response in advanced lung cancer patients.
In summary, we have provided in vitro evidence demonstrating that phosphorylation of PXN at Y118 and Y31 promoted ERKmediated Bcl-2 expression to consequently result in cisplatin resistance. Consistent observations were also seen in in vivo animal models and lung tumors from lung cancer patients. Therefore, we suggest that Src or ERK may be potential therapeutic targets in patients whose tumors show high PXN expression and are likely to be cisplatin-resistant.
MATERIALS AND METHODS

Study subjects
The study included 183 patients who underwent resection at the Department of Chest Surgery, Taichung Veteran General Hospital, Taichung, Taiwan, between June 1994 and December 2006. The tumor type and stage of each specimen was histologically determined according Cell lines A549, Ch27, H23, H358, H1355, H157 and H1299 cells were obtained from the American Type Culture Collection (ATCC) and cultured as described. CL1-5 cells were kindly provided by Dr P-C Yang (Department of Internal Medicine, National Taiwan University Hospital, Taiwan). TL-10 and TL-13 cells were culturally established from pleural effusions of three patients by the Ficoll-Paque method. The detailed methods for culture and identification were shown in pervious study. 40 These cells were cultured and stored according to the suppliers' instructions and used at passages 5-20. Chemicals and antibodies PD153035 was obtained from Calbiochem (La Jolla, CA, USA). Dasatinib was obtained from LC Laboratories (Woburn, MA, USA). Gefitinib and AZD6244 were obtained from Selleckchem.com (Houston, TX, USA). ABT-199 was obtained from ActiveBiochem (Maplewood, NJ, USA). All other chemicals were acquired from Sigma Chemical (St Louis, MO, USA) unless otherwise indicated. Anti-EGFR (epidermal growth factor receptor), antitotal Src, anti-phospho-Src (p-Src), anti-total ERK and anti-phospho-ERK (p-CREB) antibodies were obtained from Cell Signaling (Danvers, MA, USA). Anti-PXN antibody was obtained from NeoMarker (Fremont, CA, USA). AntiphosphoY31-PXN (pY31-PXN) and anti-Bcl-2 were obtained from Genetex (Irvine, CA, USA). Anti-phosphoS85-PXN (pS85-PXN), Anti-phosphoS178-PXN (pS178-PXN), Anti-phosphoS272-PXN (pS85-PXN), Anti-phosphoT538-PXN (pT538-PXN) were obtained from ECM bioscience (Versailles, KY, USA). All other antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Plasmid constructs and transfection
The PXN-overexpressing plasmid was kindly provided by Dr Salgia (The University of Chicago, USA). Mutated PXN expression constructs containing multiple-point mutations (Y31F, Y118F, Y31/118F, E286R, S272A, S85A, S178A and T538A) and DBH4 Bcl-2 overexpression constructs were constructed by the QuickChange site-directed mutagenesis system (Stratagene, La Jolla, CA, USA). The Bcl-2 P1 promoter-Luciferase plasmid and Bcl-2 overexpression plasmid was purchased from Addgene (Addgene Company, Cambridge, MA, USA). AKT (AKT1), NF-kB (p65), p38, JNK, c-Met, EGFR, Src, ERK, CREB1, Bcl-2 and PXN RNAi were purchased from National RNAi Core Facility, Academia Sinica, Taiwan (Supplementary Table 4 ). Different concentrations of expression plasmids were transiently transfected into lung cancer cells (1 Â 10 6 ) using the Turbofect reagent (Formentas, Hanover, MD, USA). 41 After 48 h, cells were harvested and whole-cell extracts were assayed in subsequent experiments.
Real-time quantitative RT-PCR analysis, western blotting and luciferase reporter assay Real-time quantitative RT-PCR analysis, western blotting and luciferase reporter assay were performed to assess gene expression as previously described. 42 Primers used for real-time PCR analysis are listed in Supplementary Table 5 .
In vivo immunoprecipitation and ChIP assays
The immunoprecipitation and ChIP procedures and quantification methods were performed as described previously. 43 The primers consisting of the oligonucleotides that encompass the promoter region of CREB are shown in Supplementary Table 5 .
Immunohistochemical analysis
Anti-mouse PXN antibodies were purchased from Neomarkers (Fremont, CA, USA). Anti-rabbit phosphorylated-PXN (Y118 and Y31) and Bcl-2 antibodies were purchased from Santa Cruz. Anti-rabbit phosphorylated ERK antibodies were purchased from Cell Signaling. The immunohistochemical procedures and quantification methods were performed as described previously. 6 MTT cytotoxicity assay
The cell lines were cultured in a humidified incubator containing 95% air and 5% CO2 at 37 1C in 96-well flat-bottomed microtiter plates containing RPMI and DMEM supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin. Before cisplatin treatment, the cells in the exponential growth phase were pretreated with overexpression and knockdown plasmids for 24 h or procaine for 2 h. After 48 h of incubation, the in vitro cytotoxic effects of these treatments were determined by MTT assay (at 570 nm) and the cell viability was expressed as a percentage of the control (untreated) cells (% of control).
Annexin-V staining
The cells were collected by trypsinization and centrifugation at 1000 g for 5 min. Following resuspension in binding buffer (10 mM HEPES-NaOH, 140 mM NaCl, 2.5 mM CaCl 2 ) at a final cell density of 1-2 Â 10 6 cells/ml, 100 ml of a single-cell suspension (1-2 Â 10 5 cells) was incubated with 5 ml annexin V-FITC and 5 ml PI for 15 min at room temperature in the dark. After addition of 400 ml of binding buffer, the samples were analyzed by using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) within 1 h. For each sample, 10 000 events were counted.
In vivo animal model experiments
For therapeutic experiments in tumor growth, tumor cells were injected subcutaneously into the back of 4-5-week-old female Balb/c nude mice. Xenograft size was measured every 3 days and tumor volume was determined as (length Â width 2 )/2. When tumors grew to 100 mm 3 , the mice were randomized to indicated groups: vehicle (DMSO), cisplatin (5 mg/kg/week), Dasatinib (5 mg/kg/week), AZD6244 (5 mg/kg/week), combined with cisplatin and Dasatinib, and combined with cisplatin and AZD6244. Drugs were administrated by intraperitoneal injection.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software program (Version 18.0; SPSS Inc., Chicago, IL, USA). The association between tumor response and PXN protein expression was analyzed by the w 2 -test. Survival plots were generated using the Kaplan-Meier method, and differences between patient groups were determined by the log-rank test. Multivariate Cox regression analysis was performed to determine OS and RFS. The analysis was stratified for all known variables (age, gender, smoking status, tumor type and tumor stage) and protein expression.
